BRPI0812777A2 - Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir - Google Patents

Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir

Info

Publication number
BRPI0812777A2
BRPI0812777A2 BRPI0812777-8A2A BRPI0812777A BRPI0812777A2 BR PI0812777 A2 BRPI0812777 A2 BR PI0812777A2 BR PI0812777 A BRPI0812777 A BR PI0812777A BR PI0812777 A2 BRPI0812777 A2 BR PI0812777A2
Authority
BR
Brazil
Prior art keywords
composition
monoclonal antibody
tumor antigen
unmarked
antibody connecting
Prior art date
Application number
BRPI0812777-8A2A
Other languages
English (en)
Inventor
Max Hasmann
Helmut Lenz
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0812777A2 publication Critical patent/BRPI0812777A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0812777-8A2A 2007-06-06 2008-06-04 Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir BRPI0812777A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07011087 2007-06-06
PCT/EP2008/004456 WO2008148546A2 (en) 2007-06-06 2008-06-04 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label

Publications (1)

Publication Number Publication Date
BRPI0812777A2 true BRPI0812777A2 (pt) 2014-12-02

Family

ID=38658220

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812777-8A2A BRPI0812777A2 (pt) 2007-06-06 2008-06-04 Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir

Country Status (12)

Country Link
US (2) US8529901B2 (pt)
EP (1) EP2155786B1 (pt)
JP (1) JP5373776B2 (pt)
KR (1) KR101169243B1 (pt)
CN (1) CN101679510A (pt)
AU (1) AU2008258859A1 (pt)
BR (1) BRPI0812777A2 (pt)
CA (1) CA2687819A1 (pt)
ES (1) ES2555784T3 (pt)
IL (1) IL201565A0 (pt)
MX (1) MX2009012838A (pt)
WO (1) WO2008148546A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101253576B1 (ko) * 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN102939538A (zh) * 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP6385060B2 (ja) * 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
CN102262155B (zh) * 2011-04-12 2013-10-09 百泰生物药业有限公司 重组人表皮生长因子生物学活性测定方法及其应用
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US20130095172A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
AU2013240137B2 (en) * 2012-03-30 2017-04-20 Leica Microsystems Cms Gmbh Methods for generating an image of a biological sample
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CA3071678A1 (en) 2013-04-16 2014-10-23 Genentech,Inc. Pertuzumab variants and evaluation thereof
SG10201809411PA (en) 2014-04-25 2018-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3386549A4 (en) * 2015-12-10 2019-08-07 City of Hope ANTIBODIES COUPLED WITH CYANINE WITH CELL PENETRATION
KR101847264B1 (ko) 2016-03-29 2018-04-10 국립암센터 항원 반응형 항체-형광염료 결합체 및 이를 이용한 표적 세포의 형광영상 검출방법
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
EP3589661B1 (en) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JP4297689B2 (ja) * 2001-04-13 2009-07-15 中外製薬株式会社 抗原の発現量を定量する方法
KR101569300B1 (ko) 2005-02-07 2015-11-13 로슈 글리카트 아게 Ｅｇｆｒ 에 결합하는 항원 결합 분자, 이를 코딩하는 벡터, 및 그의 용도

Also Published As

Publication number Publication date
US8529901B2 (en) 2013-09-10
CN101679510A (zh) 2010-03-24
CA2687819A1 (en) 2008-12-11
AU2008258859A1 (en) 2008-12-11
ES2555784T3 (es) 2016-01-08
KR101169243B1 (ko) 2012-08-02
US20110027190A1 (en) 2011-02-03
US20130323180A1 (en) 2013-12-05
WO2008148546A2 (en) 2008-12-11
EP2155786B1 (en) 2015-11-18
JP2010529060A (ja) 2010-08-26
EP2155786A2 (en) 2010-02-24
JP5373776B2 (ja) 2013-12-18
IL201565A0 (en) 2010-05-31
MX2009012838A (es) 2009-12-11
US9687568B2 (en) 2017-06-27
KR20100003371A (ko) 2010-01-08
WO2008148546A3 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0812777A2 (pt) Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
LTPA2018002I1 (lt) Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius
CY2017043I2 (el) Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
BRPI0820530A2 (pt) Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos
IL243375B (en) A human monoclonal antibody that binds to mesothelin
CY2015058I2 (el) Αντισωματα προς ανθρωπινο προγραμματισμενου θανατου υποδοχεα pd-1
BRPI0921805A2 (pt) anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
BRPI0914663A2 (pt) humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
SMT201600222B (it) Formulazione di anticorpi
EP2021373A4 (en) MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
BRPI0919545A2 (pt) anticorpos que se ligam a il-18 e métodos de purificar os mesmos
DK2459167T3 (da) SUBKUTAN ANTI-HER2-antistofformulering
SMT201700083B (it) Anticorpi monoclonali
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
DK1794586T3 (da) Monoklonale antistoffer til progastrin
BRPI0818780A2 (pt) Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
IL208517A (en) Antibody-specific monoclonal antibodies associated with humanized CD70 and methods for identifying CD70 expression
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0809677A2 (pt) Anticorpos anti-ige

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.